Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fundraising

7 Apr 2008 15:46

Amphion Innovations PLC07 April 2008 Amphion Innovations plc Fundraising and Directors Dealings London and New York, 7 April 2008 - Amphion Innovations plc (LSE: AMP)("Amphion" or the "Company"), the developer of medical and technologybusinesses, today announces that it has raised £250,000 (before expenses) by theissue of 1,136,364 new ordinary shares of 1p each in the capital of the Company(the "New Ordinary Shares") to an institutional investor by way of subscriptionat an issue price of 22 pence per New Ordinary Share to enable the Company toinvest in current and new Partner Companies and to provide working capital forthe Company. The New Ordinary Shares will represent approximately 0.87 per centof the existing Amphion share capital. Application will be made to the London Stock Exchange for the New OrdinaryShares to be admitted to trading on AIM. The New Ordinary Shares will, whenissued, rank equally in all respects with the existing Ordinary Shares,including the right to receive any dividend or other distribution declared, madeor paid following Admission. It is expected that Admission will become effectiveand that dealings in the New Ordinary Shares will commence 11 April 2008. Amphion also announces today that New Ordinary Shares have been issued to Boardmembers Richard Mansell-Jones and R. James Macaleer who, in lieu of theirdirectors' fee for the period 1 January to 31 March 2008, received their fullremuneration in the form of Ordinary Shares priced at 22p being the closingmid-market price on 1 April 2008. Richard Mansell-Jones, Chairman of Amphion, received 40,227 Ordinary Shares,bringing his total holdings of the Company to 2,602,792 representing 2 per centof the Company's issued Ordinary Share capital. Pursuant to Rule 13 of the AIMRules this constitutes a related party transaction and the independent Directorsconsider having consulted with its Nominated Adviser that the terms of thetransaction are fair and reasonable insofar as its shareholders are concerned. R. James Macaleer received 20,114 Ordinary Shares, bringing his total holding ofthe Company to 19,871,563 representing 15.26 per cent of the Company's issuedOrdinary Share capital. Chief Executive Officer, Richard Morgan and President and Chief FinancialOfficer, Robert Bertoldi, who are also both Board members, have received NewOrdinary Shares as part of their incentive compensation. Richard Morgan received379,056 Ordinary Shares priced at 22p, bringing his total holdings of theCompany to 21,173,211 representing 16.26 per cent of the Company's issuedordinary share capital. Robert Bertoldi received 31,607 Ordinary Shares pricedat 22p, bringing his total holdings of the Company to 5,674,844 representing4.36 per cent of the Company's issued Ordinary Share capital. In addition to the 410,663 Ordinary Shares issued to Richard Morgan and RobertBertoldi, 50,893 Ordinary Shares were also issued to five employees of theCompany as part of their incentive compensation. Admission of the 1,658,261 New Ordinary Shares, ranking pari passu, is expectedon 11 April 2008. Following admission of the New Ordinary Shares, the Company will have130,196,893 ordinary shares in issue with each ordinary share holding one votingright. For further information please contact Amphion Innovations plcCharlie Morgan, Director of Communications+1 212 210 6224 Cardew GroupTim Robertson/ Jamie Milton/ Matthew Law+44 020 7930 0777 Charles Stanley Securities - Nominated AdviserMark Taylor / Freddy Crossley+44 20 7149 6000 About Amphion Innovations plc Amphion (LSE: AMP) builds shareholder value in high growth companies in themedical and technology sectors, by using a focused, hands-on company buildingapproach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proventechnologies targeting substantial commercial marketplaces, each in excess of $1billion. Each Partner Company is chosen with the goal of achieving an exitvaluation in excess of $100 million. On the web: www.amphionplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Jun 20067:01 amRNSAppointment
6th Jun 20067:01 amRNSRe Agreement
5th Jun 20063:16 pmRNSThe Shafallah Center
2nd Jun 20065:01 pmRNSDr David Evans
1st Jun 20067:00 amRNSAnnual Report and Accounts
23rd May 20067:00 amRNSDirector/PDMR Shareholding
22nd May 20061:41 pmRNSDirector/PDMR Shareholding
19th May 20065:12 pmRNSDirector Share Transaction
15th Mar 20069:25 amRNSCompletion of a Financing
8th Mar 20067:04 amRNSFinal Results
2nd Mar 20069:12 amRNSMotif BioSciences
27th Feb 20064:56 pmRNSNotice of Results
23rd Feb 20067:02 amRNSRe: WellGen Financing
3rd Jan 20067:01 amRNSAdditional Investments
5th Dec 200512:48 pmRNSDirector Shareholding
10th Oct 20057:00 amRNSAcquires a stake
21st Sep 20057:00 amRNSStake in Spin-Out Company
30th Aug 20057:00 amRNSAmphion Invests in WellGen
25th Aug 20054:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.